Therapeutic implications of cellular and molecular biology of cancer stem cells in melanoma by Dhiraj Kumar et al.
REVIEW Open Access
Therapeutic implications of cellular and
molecular biology of cancer stem cells in
melanoma
Dhiraj Kumar1, Mahadeo Gorain1, Gautam Kundu2 and Gopal C. Kundu1*
Abstract
Melanoma is a form of cancer that initiates in melanocytes. Melanoma has multiple phenotypically distinct
subpopulation of cells, some of them have embryonic like plasticity which are involved in self-renewal, tumor
initiation, metastasis and progression and provide reservoir of therapeutically resistant cells. Cancer stem cells (CSCs)
can be identified and characterized based on various unique cell surface and intracellular markers. CSCs exhibit
different molecular pattern with respect to non-CSCs. They maintain their stemness and chemoresistant features
through specific signaling cascades. CSCs are weak in immunogenicity and act as immunosupressor in the host
system. Melanoma treatment becomes difficult and survival is greatly reduced when the patient develop metastasis.
Standard conventional oncology treatments such as chemotherapy, radiotherapy and surgical resection are only
responsible for shrinking the bulk of the tumor mass and tumor tends to relapse. Thus, targeting CSCs and their
microenvironment niche addresses the alternative of traditional cancer therapy. Combined use of CSCs targeted
and traditional therapies may kill the bulk tumor and CSCs and offer a promising therapeutic strategy for the
management of melanoma.
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Background
Tumor initiating cells having stem cell characteristics
were first discovered in leukaemia and later in solid tu-
mors which recently has become an important area in
cancer research [1]. These stem like tumor cells, termed
as cancer stem cells (CSCs) govern tumor progression,
angiogenesis and metastasis via modulating certain spe-
cific pathways which depends upon the type of the tis-
sue. CSCs have similar physiological properties as
normal stem cells, like self-renewal, differentiation and
indefinite proliferation ability which might be the main
cause of tumor progression [1]. Conventional anti-
cancer treatments eradicate bulk of tumor mass but it is
ineffective for CSCs and hence could be the reason for
tumor reoccurrence and progression. CSCs have been
identified in hematopoietic cancer and solid tumors like
brain, breast, prostrate, colon, pancreatic, lung and most
recently in melanoma.
Malignant melanoma is a highly aggressive and drug-
resistant cancer [2]. Several groups have shown the exist-
ence of tumor heterogeneity with undifferentiated mo-
lecular signatures having high tumorigenic potential with
embryonic-like differentiation which strongly suggest the
presence and the involvement of CSCs in melanoma.
Although the concept of CSCs is well accepted for many
tumors, but the existence of CSCs in melanoma has been
the subject of debate. Initially, Fang et al. and Monzani et
al. have shown the existence of stem cell-like subpopula-
tion in CD20+ and CD133+ melanoma cells [3, 4]. Subse-
quent studies support the involvement of CSCs in human
melanoma progression using ABCB5 and CD271 as
markers [5, 6]. Recently, Luo et al. have provided signifi-
cant evidence and shown the existence of CSCs in melan-
oma by using ALDH, an intercellular stem cell marker in
melanoma [7]. Moreover, CSCs are responsible for EMT,
metastasis and angiogenesis in autocrine or paracrine
manner [8, 9]. Tumor microenvironment also plays a
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major role during the melanoma progression. For ex-
ample, stroma-derived osteopontin regulates the side
population (SP) enrichment and controls angiogenesis
and metastasis in melanoma [10]. Hypoxia inducible fac-
tor (HIF) and transcription factor like Snail are expressed
in CSCs derived from glioma and melanoma that leads to
enrichment of CSC, self-renewal and differentiation and
control angiogenesis and metastasis [11, 12]. CSCs are re-
sponsible for recurrence in most of tumor which associ-
ated with modulation of tumor microenvironment and
immune escape mechanisms [13]. Many studies showed
that CSCs exhibit specific intracellular molecular proper-
ties that are distinct with their rest of the bulk tumor cells
which lead to limited response against conventional treat-
ments [14, 15]. Additionally, the expression of various
miRNAs in CSCs strongly correlates with melanoma pro-
gression which helps in the modulation of tumor micro-
environment through targeting the various specific
signaling pathway [16–18]. Traditional chemotherapy or
radiation therapies are not sufficient to eliminate CSCs
from the tumors, therefore, understanding the cellular
and molecular biology of CSCs are essential for the identi-
fication of novel CSCs-targeted therapies.
Melanoma CSCs and their unique markers
Several lines of evidences suggested the presence and in-
volvement of CSCs in melanoma initiation and progression
[3]. Identification of highly aggressive undifferentiated sub-
populations with embryonic-like plasticity within the mel-
anoma has established the link between the tumor
progression and CSCs [3, 4]. The melanoma derived
spheres demonstrated a significant differentiation potential
capable of giving rise to melanocytes, adipocytes, osteo-
cytes and chondrocytes. These spheres also exhibit high
self-renewal ability both in vitro and in vivo [3]. CSCs are
thought to express cell surface and intracellular markers
traditionally associated with tissue specific stem cells which
are responsible for tumor heterogeneity [19]. Earlier stud-
ies suggested that melanoma stem cells can be character-
ized based on the expression of markers such as CD20,
CD133 and MDR1 as shown in Table 1. However, a firm
correlation between expression of markers with various
other properties such as self-renewal ability, high tumori-
genic potential, multilineage differentiation in CSCs is yet
to be studied [3–5].
Previous studies demonstrate that melanoma cells or
clinical specimens undergoing chemoresistance overex-
press a number of stem cell markers including CD133
and ABCG2 [4]. Furthermore, Nordvig et al. reported
that CD133+ keratinocytes exhibit high mitochondrial
potential that may have clinical implications in non-
melanoma skin cancer [20]. Roudi et al. have studied
gene-expression profiling in CD133+ cells compared
with CD133− D10 cells. The data demonstrated that 130
genes were upregulated including ABC transporter
super-family (ABCC1, ABCG2 and ABCC6), while 61
genes were downregulated including apoptosis modify-
ing genes (CASP8 and TNFRSF4). These data indicate
that CD133+ D10 cells are highly resistant and aggres-
sive in melanoma model [21]. More recently, Kumar et
al. have shown that CD133+ melanoma specific CSCs
maintain long term tumorigenic potential under in vivo
condition [15]. Furthermore, stem cell associated
markers, nestin and CD133 are highly expressed on cir-
culatory melanoma cells which might represent an index
of poor prognosis [22]. Other group has shown that re-
ceptor activator of NF-κB (RANK) expressing metastatic
melanoma cells co-expressed ABCB5 and CD133 [23].
In accordance with previous reports, Schatton et al. have
identified malignant melanoma-initiating cells (MMICs)
which are capable of self renewal and differentiation and
enriched on the basis of preferential expression of
markers such as ABCB5 (a member of ATP-binding cas-
sette) [5]. Moreover, it has also been reported that the
amplification of ABCB5 is a predisposing factor for
melanoma development which further emphasize the
specific role of stem cells in melanoma growth [24]. In
addition, ABCB5+ melanoma cells showed tumor
Table 1 CSCs markers are used for their characterizations in
melanoma
Markers Associated properties and functions References
CD133 • Tumor initiation
• Maintain long-term tumorigenic potential
• Chemoresistance
• Activates p38 MAPK pathway
• Induces metastasis and angiogenesis
[4, 15]
ABCG2 • Tumor initiation [4]
CD271 • Associated with metastasis
• Establish tumor heterogeneity
• Maintain long-term tumor growth
[6]








CD20 • Highly enrich in melanosphere
• Exhibit self-renewal
[3]
PD-1 • Highly tumorigenic
• Help in the evasion of tumor immunity
[25]
VEGFR1 • Higher tumor growth
• Vasculogenic mimicry





JARID1B • Give rise to highly proliferative progeny
• Self-renewal
• Exhibits continuous tumor growth and
metastasis
• Regulates Jagged1/Notch1 signaling
[30]
Kumar et al. Molecular Cancer  (2017) 16:7 Page 2 of 18
initiation at the level of 1x105 cells, whereas 100-fold more
ABCB5− cells are required to develop tumor under in vivo
condition indicating the importance of CSCs in melanoma
progression. In addition, PD-1+ and B7.2+ cells in human
melanoma are responsible for higher tumorigenicity com-
pared with PD-1− and B7.2− cells respectively. It has also
been observed that the expression of PD-1 and B7.2
markers are coexpressed with ABCB5 [25]. Further, Fang
et al. showed that CD20+ fraction from melanoma cells
exhibit multipotent properties under in vitro and in vivo
conditions [3]. The expression of VEGFR1 is highly upreg-
ulated and associated with tumor progression in malig-
nant melanoma-initiating cells. In this study, the
expression of VEGFR1 and its downstream signaling play
a crucial role in ABCB5+ MMIC which govern the vascu-
logenic mimicry (VM) and higher tumor growth [9].
Moreover, Schlaak et al. have showed that elimination of
CD20+ cells lead to regression of metastatic melanoma
[26]. Furthermore, CXCR6 is a newly defined biomarker
for identification and characterization of aggressive melan-
oma specific CSCs [27]. Civenni et al. have also character-
ized the CSCs based on expression of CD271, a specific
melanoma stem cell marker [6]. In contrast, Boyle et al.
have demonstrated that CD271 expression is unstable and
not consistently linked to tumorigenicity in clinical melan-
oma patient’s specimens [28]. Additionally, Li et al. have
shown that the expression of CD271 is epigenetically reg-
ulated through DNA methylation. In this study, they have
shown that expression of CD271 induced drastically when
treated with 5-aza (an inhibitor of the methylase enzyme)
for 6 days demonstrating that DNA methylation is in-
volved in regulation of CD271 expression [29].
Roesch and their colleagues demonstrated that JAR-
ID1B+ melanoma cells are slow-cycling that are respon-
sible for giving rise to a highly proliferative progeny [30].
In addition, Kumar et al. have shown the existence of
side population (SP) in melanoma which exhibits the
properties of CSCs [10]. Recently, Luo et al. have well
established the concept of CSCs in melanoma based on
the intracellular stem cell marker ALDH where they
have shown that ALDH+ cells fulfil the criteria of self-
renewal and differentiation of CSCs upon serial trans-
plantation into NOD/SCID mice. ALDH1A is a super-
family of detoxifying enzymes which metabolize a wide
variety of intracellular aldehydes therefore providing
chemoresistance in human melanoma stem cells, thus
governing cancer cell proliferation and survival [7]. Re-
cently, it has been observed that CD44high/ALDH1A1high
cells were significantly higher in melanoma specimens
which suggest a possible candidate for targeted therapy
of skin cancer aiming to CSCs [31]. Dioxin receptor
(AhR) integrates signaling pathways associated with
xenobiotic metabolism and tissue or organ homeostasis.
AhR is involved in dualistic role in tumor development.
However, AhR knockdown increased ALDH1A1 activity
and enhances B16F10 melanoma growth through main-
taining cancer stem-like phenotypes. Further, knockdown
of ALDH1A1 reduced the levels of CD133+/CD29+/CD44+
cells, melanosphere size and expression of Sox2, a pluripo-
tency factor in AhR knockdown cells [32]. Taken together,
these results demonstrate that existence of a subset of cells
in melanoma with CSC-like features that can be identified
based on specific unique markers.
The crosstalk between melanoma CSCs and angiogenesis
Angiogenesis is an important hallmark of tumor develop-
ment. Most of the genes that are upregulated in aggressive
melanoma are known to be involved in angiogenesis and
vasculogenesis, such as CD144, EPHA2 and LAMC2.
These molecules are required for formation and mainten-
ance of blood vessels. Some of these genes are also involved
in vasculogenic mimicry leading to melanoma progression
and metastasis [33]. Jin et al. have demonstrated the exist-
ence of EGFR-Akt-Smad signaling in stem like cells which
promotes tumor angiogenesis by ID3 regulated cytokine in-
duction [34]. Neovascularization in tumor is often associ-
ated with CSC-derived endothelial cells (ECs). Kumar et al.
and Bussolati et al. have shown that renal and melanoma
derived-CSCs are able to differentiate into endothelial like
cells when cultured in endothelial cell growth specific
medium [15, 35]. Cumulative evidences have shown that
CSCs are involved in the angiogenesis phenomenon.
Monzani et al. have demonstrated that WM115 cells ex-
press angiogenic factors like VEGF, VEGFR-2, Ang1/2 and
Tie2 along with melanoma specific CSCs signaling such as
Notch4 [4]. Since melanoma specific CSCs have high de-
gree of differentiation plasticity, they may contribute to the
de novo formation of tumor blood vessels via a process
termed vasculogenic mimicry (VM) [33]. In accord with
these results, Frank et al. have demonstrated that ABCB5+
human melanoma cells are specifically associated with vas-
culogenic mimicry by expressing endothelial specific and
other angiogenic proteins. The same group has shown that
human melanoma ABCB5+ subpopulation preferentially
expresses the vasculogenic differentiation markers like Tie1
and CD144 (VE-cadherin) which are distinct from those
expressed on mature CD31+ tumor endothelial cells [9].
CD133+ melanoma specific CSCs exhibit the functional
tube formation and maintain the endothelial cell alignment
through secretory factors present in their conditioned
medium [15] as shown in Fig. 1. In addition, ABCB5+ and
CD133+ melanoma specific CSCs preferentially express
VEGFR1 and VEGF that are essential for VM in human
melanoma cells [9, 15].
Lai et al. have identified that CD133+ and ABCB5+ sub-
populations are colocalized in the perivascular niche of
melanoma. This perivascular niche contains CD144 (VE-
cadherin)+ melanoma cells with vessel like channels. They
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have further investigated the role of CD133+ cells in vascu-
logenic mimicry using CD133+/GFP+ melanoma cells
under in vivo conditions. They have observed that vascular
niches containing mosaic vessels that are partially lined up
by both CD144+/GFP+ channels-forming melanoma cells
and CD144+/GFP− mouse endothelial cells [36]. Schnegg
et al. have also demonstrated that perivascular niches ex-
hibit higher accumulation of CD133+ and CD271+ melan-
oma stem cells [37]. It has been reported that CSCs from
glioblastoma help in tumor vascularisation through recruit-
ment of endothelial progenitor cells (EPCs) via VEGF and
SDF1 [38]. Recently, it has been observed that melanoma
cells educate mesenchymal stromal cells towards vasculo-
genic mimicry through various angiogenic factors [39].
Furthermore, a recent study shows that CD133+ D10 mel-
anoma cells exhibit a significant induction of early
angiogenesis under in vivo condition compared with
CD133− D10 cells [40]. Interestingly, VM-forming melan-
oma cells are positive for CD271 [41] and the data sup-
ports that VEGFR1 and PKCα signaling control melanoma
VM [42].
Moreover, Harell et al. have showed that primary melan-
oma induces sentinel lymph node lymphangiogenesis
prior to initiation of dissemination [43]. Subsequent study
demonstrated that VEGF-A in cutaneous squamous cell
carcinoma and VEGF-C in melanoma induces the sentinel
lymph node lymphangiogenesis and promotes lymphatic
metastasis [44, 45]. However, the detailed mechanism of
melanoma specific CSCs in lymphangiogenesis need to be
investigated further. All these observations clearly empha-
sized the role of melanoma specific CSCs in angiogenesis



























Fig. 1 Role of CSCs in melanoma growth, metastasis and angiogenesis. Cytokines and growth factors transcriptionally reprogram the several
transcriptional factors that mediate EMT. During EMT, cells lose the epithelial markers and acquired the mesenchymal phenotypes which help in the
invasion. CSCs degrade ECM proteins through MMPs which enhance the invasion properties. Further, microenvironment associated factors trans-
differentiate CSCs into endothelial-like phenotype that leads to enhance neovascularisation. Additionally, angiogenesis is enhanced through upregulation
of CSCs-derived angiogenic factors such as VEGF in melanoma. The CSCs-derived exosomes contain specific miRNA that control the endothelial barriers
and promote intravasation that ultimately regulates metastasis. Upon change in physiology of CSC niche, dormant metastatic CSCs reactivate and exhibit
MET phenotype leading to establishment of secondary tumors. CSCs: cancer stem cells; EMT: epithelial to mesenchymal transition; MET: mesenchymal to
epithelial transition; ECM: extracellular matrix; MMPs: matrix metalloproteinases; VEGF: vascular endothelial growth factor
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Melanoma CSCs in metastasis and tumor recurrence
Metastasis is the intermediate phenomenon of the tumor
development. Tumor metastasis is established by several
phenotypic changes and processes such as invasive growth,
escape from primary site, intravasation, lymphatic and
haematogenous survival, extravasation and colonization at
distant organs. During metastasis, tumor cells lose or gain
several adhesion molecules such as ALCAM, VE-cadherin,
L1-CAM, integrin β3, ICAM-1, E-cadherin and N-
cadherin [46]. Malignant melanoma is a highly metastatic
disease having survival period of less than 5 years. It mostly
metastasizes to lungs and also affects other visceral organs.
Several clinical reports suggest that regional lymph node
metastasis is a determinant of outcome for patients with
melanoma. The presence of regional lymph node metasta-
sis is commonly used as an indication for systemic and
adjuvant therapy. However, the potential risk of recurrence
greatly varies in each individual due to heterogeneous na-
ture of the tumors [47].
Al Dhaybi et al. and Rappa et al. have shown the exist-
ence of CD133+ CSCs in development of malignant mel-
anoma and their potential to metastasize in lymph
nodes, lung and/or other visceral organs. These cells
expressed low level of proliferative maker Ki-67 that
may associate with the chemoresistant ability of CSCs
[48, 49]. Fusi et al. have observed the co-expression of
CD133 with Nestin on circulatory melanoma cells.
These data highlighted that the patient survival rate is
low with Nestin overexpressed circulatory melanoma
cells compared to low Nestin expressed cells [22]. Add-
itionally, Klein et al. observed significant increase in the
expression of stem cell markers, CD133, CD166 and
Nestin in primary and metastatic melanoma cells [50].
Furthermore, it has been shown that CD20+ CSCs are
responsible for metastasis [26]. Moreover, Civenni et al.
and de Waard et al. have also established the link be-
tween metastasis and CD271+ or ABCB5+ melanoma
stem cells [6, 51]. In addition, Kumar et al. have shown
that side population in melanoma cells have higher
metastatic capacity as compared with those of non-side
population [10]. Several reports suggest that ALDH1 is a
potential marker in CSCs derived from melanoma. Gen-
etic ablation of ALDH1A1 by its specific shRNA resulted
not only significant reduction in tumor growth but also
exhibited significant decrease in metastatic burden in
melanoma [52]. Furthermore, clinical data strongly sug-
gests that RANK is highly upregulated on melanoma-
initiating cells and the expression of RANK is higher in
metastases as compared to primary tumor [23]. Zhao et
al. have recently showed that CD133+CD44+ melanoma
CSCs are highly metastatic towards lung [53]. During in-
vasion, tumor cells exhibit different phenotypic changes
through epigenetic modifications. Studies revealed that
combined expression of EZH2, H3K4me2 and
H3K27me3 might correlate with potential CSCs proper-
ties. Moreover, the expressions of EZH2, H3K4me2 and
H3K27me3 were enhanced significantly at the invasive
site of tumor. However, expressions of these molecules
were less in metastatic sites as compared to patients
with primary melanoma cases [54].
Additionally, recent clinical data showed that there were
significant increase in the number of ABCB5+CD271
+RANK+ CSCs in circulatory tumor cells (CTCs) at late
stage of melanoma. These data indicate that CTCs are
highly enriched in CSCs which are responsible for estab-
lishment of distant secondary tumors [55]. Ojha et al. have
reported that autophagy in CSCs establish a potential link
between chemoresistance, metastasis and recurrence in
several tumors [56]. Several lines of evidences suggest that
some of the metastasized tumor solitary cells exist in a qui-
escent like state accompanied by decreased expression of
proliferation specific markers. The tumor dormancy might
caused by several mechanisms such as stress induced by
microenvironment, programming of the transcriptional
factors and therapeutic treatment of the primary tumor
[57]. Additional data also suggest that CSCs are predomin-
antly quiescent in nature and that may contribute to dor-
mancy [58]. Changes in microenvironment including pro-
proliferative, pro-inflammatory and pro-angiogenic mole-
cules may lead to the mobilization and activation of dor-
mant CSCs [57]. Stereotactic body radiation therapy
promotes recurrence of melanoma through mesenchymal
stem cells (MSCs) recruitment and pericytes differentiation
leading to vasculogenesis [59]. The exosomes enhance the
metastatic behaviour of primary tumors by educating bone
marrow progenitors through MET (a receptor tyrosine kin-
ase) from highly metastatic melanoma [60]. Gao et al. have
demonstrated the mediator and suppressor molecules for
metastatic reactivation in breast cancer cells by using for-
ward genetic screening approach in mice [61]. The
immune-surveillance may induces dormancy in single cu-
taneous malignant melanoma cells by blocking their prolif-
eration cycle [62]. All these results suggest that CSCs are
involved in the formation of metastatic lesion and tumor
recurrence (Fig. 1).
Melanoma CSCs and EMT
In the process of metastasis, cells need to disseminate
from their primary site where tumor cells lose the epithe-
lial phenotype and gain the mesenchymal status termed as
epithelial-to-mesenchymal transition (EMT). Upon reach-
ing to secondary site, these reprogrammed cells exhibit a
reversal process designated as mesenchymal-to-epithelial
transition (MET) as shown in Fig 1. Mounting evidences
have demonstrated that EMT induced by different factors,
is associated with tumor aggressiveness and metastasis
and these cells share molecular characteristic with CSCs
[63]. EMT is driven by several transcription factors (TF)
Kumar et al. Molecular Cancer  (2017) 16:7 Page 5 of 18
such as Snail, Slug, Twist and Zeb and studies showed that
EMT-inducer control the progression of malignant melan-
oma [63, 64]. Recent studies also showed that silencing of
CD133 downregulates Slug and Snail expression [15]. Yao
et al. have shown that epithelial splicing regulatory protein
1 (ESRP1) is associated with EMT in addition to Slug,
Snail and Zeb in human malignant melanoma. It has been
shown that the expressions of epithelial markers were
higher in tumors with full-length ESRP1. In contrast, the
expression of mesenchymal markers is higher in tumors
with low level of ESRP1 [65]. Recent studies have
highlighted that EMT-inducer has antagonistic function in
melanoma progression. In melanocytes, the expressions of
Snail2 and Zeb2 were found to be higher and act as onco-
suppressor whereas Twist1 and Zeb1 promote neoplastic
transformation of melanocytes and aberrantly reactivate in
melanoma [66]. Other studies have shown that Slug regu-
lates Zeb1 expression in melanoma at transcriptional level
through binding to the E-boxes of promoter [64]. Guo et
al. have showed that BRAF activates long non-coding
RNA (BANCR) that induces EMT phenomenon and con-
tribute to cancer cell migration [67].
Several lines of evidences suggest that EMT plays a cru-
cial role in tumor metastasis and recurrence which is
tightly linked with the CSCs biology. Accumulative data
indicate that CD133+ cells exhibit EMT phenotype and
maintained stemness properties [68, 69]. In addition,
CD133 facilitates EMT through interaction with ERK
pathway [68]. The study also revealed that S100A4, a mas-
ter mediator for EMT maintains tumor-initiating cells
(TICs) [70]. Several reports indicate that EMT promotes
CSCs phenotype [70, 71]. Mani et al. have demonstrated
that overexpression of Twist and Snail enhances EMT in
immortalized human mammary epithelial cells that re-
sulted in acquisition of CD44high/CD24low expression and
higher mammosphere-forming ability [72]. Zeb1 expres-
sion is closely associated with maintenance of CD133
+CD44+ CSCs-like properties in B16F10 cells that include
colony formation, drug resistance, migration and invasion.
Knockdown of Zeb1 leads to inhibition of tumorigenicity
and metastasis in CD133+CD44+ B16F10 specific CSCs. In
addition, downregulation of Zeb1 reverse the EMT
phenotype of CD133+CD44+ CSCs. These data suggested
that Zeb1 maintained the CSCs properties and EMT
phenotype in melanoma cells [73]. Downregulation of
Zeb1, Twist1 and Snail1 attenuates the invasive properties
of uveal melanoma cells [74]. GLI transcription factor is
identified as the effectors of the Hedgehog signaling path-
way. Apart from Zeb, Snail and Twist that regulate E-
cadherin and GLI-2 forms a complex with Zeb1 and ex-
hibits the repression of E-cadherin in human melanoma
cells [75]. It is well documented that microphthalmia-
associated transcription factor (MITF) determine the cell
fate of melanocyte. In addition, Zeb2 is needed for proper
differentiation of melanocyte through regulation of MITF-
ZEB1 transcription network. Knocking down of Zeb2
leads to significant downregulation of MITF and concomi-
tant upregulation of Zeb1, Vimentin and Fibronectin re-
sulted in enhanced melanoma progression [76]. Recent
study also supports that insulin-like growth factor binding
protein 5 (IGFBP5) acts as a tumor suppressor in human
melanoma by inhibiting EMT phenotype and attenuates
the expression of stem cell markers such as Nanog, Sox2,
Oct4, KLF4 and CD133 [77]. In contrast, immune-related
GTPase family protein IRGMI induces B16 melanoma cell
migration, invasion and EMT through F-actin
polymerization [78]. In addition to EMT, the mesenchy-
mal to amoeboid transition (MAT), a second type of mo-
tility shift is essential for melanoma tumor progression.
The programming of MAT exhibits increased in stem-like
and colonogenic features of melanoma cells. Overexpres-
sion of EphA2 or RacN17 in melanoma cells induces
MAT like phenotype which leads to increase in tumor in-
vasion [79].
Several solid tumors including melanoma exhibit extra-
cellular acidosis. Peppicelli et al. showed that exposing
melanoma cells with an acidic extracellular environment
(pH 6.7) upregulate the expression of mesenchymal
markers such as N-cadherin, Vimentin whereas the ex-
pression of epithelial specific marker such as E-cadherin
was found to be downregulated. Further, these data also
suggest that acidic environment enhanced the melanoma
cell invasion and lung colonization through upregulation
of MMP-9 activity [80]. Apart from several cytokine and
growth factor, TGFβ acts as key player to induce EMT in
several cancers including breast and melanoma [72, 81].
In addition, TGFβ also promotes amoeboid feature that
leads to higher melanoma migration and dissemination
[82]. Overall, these reports indicate that CSC is linked
with EMT features in association with several microenvi-
ronmental factors (Fig. 1).
Role of CSCs in regulation of immune cells in melanoma
Compelling evidences suggest that tumors are immuno-
genic in nature and melanoma is one of the well charac-
terized model [83]. Melanoma cells display multiple
antigens and peptide epitopes that help the host immune
system to respond either serologically or through cell-
mediated mechanisms [83]. However, the question
remained unsolved why tumors cannot be eliminated by
the immune system. CSCs are responsible for recurrence
of tumors and are associated with immune escape mech-
anism [13]. Therefore, to prevent the contribution of
CSCs in tumor growth, several groups have studied
whether the effector immune cytotoxic cells like NK
cells, CD8 T cells and γδT cells could eliminate the
CSCs compartments [84].
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Recently, it has been shown that anti-apoptotic proteins
such as Bcl2, Bcl-xl or survivin not only protect CSCs
against chemotherapeutic agents, but also enhance resist-
ance for apoptosis-inducing immune effectors like NK- or
T- cells [13]. The data revealed that due to low level of ex-
pression of MHC class I molecule, these CSCs are poorly
recognized by T lymphocytes. However, CSCs can be elim-
inated by γδT lymphocytes upon sensitization with bis-
phosphonate zoledronate [85]. Recent data demonstrate
that CSCs derived from colon cancer, glioblastoma as well
as melanoma can be recognized by NK cells [84]. In con-
trast, Pietra et al. have shown that melanoma cells impair
the function of NK cells through inhibiting the expression
of major receptors including NKp30, NKp44 and NKG2D
which are associated with cytolytic activity. Further, they
have observed that this inhibitory effect was primarily me-
diated by indoleamine 2,3-dioxygenase (IDO) and prosta-
glandin E2 (PGE2) [86]. Moreover, overexpression of
6 kDa early secreted antigenic target (ESAT-6), a glycosyl-
phosphatidylinositol (GPI)-anchored form and secreted
interleukin (IL)-21 in B16F10 CD133+CD44+ CSCs leads
to activation of anti-ESAT-6 and interferon (IFN)-γ corre-
lates with enhanced anti-melanoma efficacy and prolonged
survival of melanoma bearing mice [53]. It has been shown
that IL-2 and IL-15 activate NK cells and exhibit enhanced
cytotoxicity against CSCs derived from melanoma and
breast cancer [87, 88]. Moreover, NK cells preferentially
eliminate CD24+/CD44+, CD133+ and ALDHbright CSCs in
variety of human cancer cell lines through upregulation of
NKG2D ligands [89]. Schattan et al. have shown that
ABCB5+ malignant melanoma initiating cells exhibit lower
expression of melanoma associated antigens such as
MART-1, ML-IAP, NY-ESO-1 and MAGE-A which might
help them in escaping from immune surveillance mechan-
ism. Furthermore, ABCB5+ melanoma cells inhibit T-cell
activation through IL-2 and induce CD4+CD25+FoxP3+
regulatory T (Treg) cells via B7.2 dependent manner [25].
However, CD271+ melanoma cells does not express TYR,
MART1 and MAGE antigens which propel them for im-
mune resistance against T cells [90]. Moreover, overexpres-
sion of CD271 in melanoma cells suppressed melanoma-
specific cytotoxic T lymphocytes (CTLs) under in vitro
conditions. Additionally, CTLs-derived IFN-γ induces
CD271 expression in melanoma cells that is associated
with downregulation of production of melanoma antigens
[91]. These data demonstrate a novel mechanism for eva-
sion of anti-tumor immunity. In contrast, CD133+ melan-
oma CSCs express high level of cancer/testis (CT) antigens
which make them more susceptible against CD8+ T lym-
phocytes [92]. Recently, a new study showed that CD133+
murine melanoma cells express DDX3X antigen which is
immunogenic and able to protect melanoma growth in T-
cell dependent manner [93]. Further, IL-6 induces melan-
oma differentiation whereas IL-10 supports the enrichment
of undifferentiated melanoma stem like compartment [94].
Immune system also regulates the EMT process which is
consistent with earlier findings. Kudo-Suito et al. showed
that Snail-induced EMT accelerates cancer metastasis
through invasion and induction of immunosuppression by
CD4+Foxp3+ Treg cells [95].
Signaling mechanism in melanoma specific CSCs
In past, significant progress has been made towards un-
derstanding the molecular mechanism of malignant mel-
anoma. Several reports suggest that CSCs are responsible
for limited tumor response against conventional treatment
due to specific intracellular molecular properties [14].
Thus, delineating the signaling pathways by which CSCs
control tumor-protective mechanisms will provide the
better understanding of tumor relapse.
Signaling mechanism has been extensively studied in
embryonic stem cells for their maintenance or self-
renewal and these are common in CSCs. Khalkhali-Ellis
et al. demonstrated that Nodal which maintain pluripo-
tency of embryonic stem cells and plasticity of melan-
oma CSCs, interact with heterodimeric receptors of
Activin I and II in embryonic stem cells whereas it binds
with TGFβR1 and II in metastatic melanoma [96]. Alco-
hol consumption causes the risk associated with several
human cancers. Recent study showed that ethanol ex-
posure to FEMX-I melanoma cells increase the percent-
age of CD271+ CSCs. Ethanol activates NF-κB by
decreasing its p50 homodimers which leads to enhance-
ment of CD271 expression [97]. Melanoma specific
CSCs are involved in establishment of metastases that is
determined by several signaling cascades. Sonic hedge-
hog (Shh), Wnt or Notch regulatory signaling pathways
modulate the differentiation plasticity and promote self-
renewal of stem cells [98]. Several reports have shown
the presence of these signaling pathways and their thera-
peutic targets in various types of stem cells. Geng et al.
have shown that Hedgehog (HH) pathway play a vital
role in development of melanogenesis in murine melan-
oma models [99]. Moreover, abolishment of HH-GLI
signaling pathway drastically attenuates the self-renewal
and tumor initiating potential of ALDHbright melanoma
CSCs [100]. In addition, Pandolfi et al. have shown that
effectors of HH signaling, GLI1/2 regulates transcription
factor E2F1 which is essential for cell proliferation and
tumor progression in melanoma. Further, E2F1 modu-
lates iASPP (inhibitor of apoptosis-stimulating protein of
p53) by directly binding to the promoter region of
iASPP and enhance the proliferation indicating that HH-
GLI-E2F1-iASPP axis is essential for melanoma progres-
sion [101]. Moreover, Wnt signaling has been implicated
in regulation of self-renewal and proliferation of normal
stem and cancer cells [98]. High level of Wnt receptor,
FZD7 is associated with enhanced metastatic potential
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of melanoma cells. Knocking down of FZD7 suppressed
JNK activation and metastatic growth in melanoma
[102]. Similarly, Notch signaling plays a critical role in
regulating cell to cell communication during embryo-
genesis, cellular proliferation, differentiation and apop-
tosis [103]. Notch receptors cleaved by γ-secretase and
TACE (Tumor Necrosis Factor-α-Converting Enzyme)
resulted in release of NICD (Notch Intracellular Do-
main) that translocate into nucleus and regulate the pro-
moter activity of various genes. Attenuation of γ-
secretase and TACE leads to downregulation of NICD2
and Hes1 which preferentially inhibit melanosphere for-
mation indicating that Notch2 regulates melanoma pro-
gression in CSCs [104]. It has been also shown that
Notch4 promotes invasion and metastasis in melanoma
stem-like cells [105]. Additionally, Akt regulates nucleo-
cytoplasmic shuttling of NICD4 [106]. In addition, acti-
vated Notch1 increases the stability of β-catenin that
play important role in melanoma cell migration and pro-
liferation [107]. Recent data showed that Notch1 signal-
ing is highly augmented in CD133+ CSCs in melanoma.
NICD1 binds to the promoter region of CD133 and
transcriptionally regulates its expression. Further,
Notch1-CD133 signaling axis activates p38-MAPK path-
way that leads to AP-1-DNA binding and regulates the
expression of MMPs and VEGF that are essential for
metastasis and angiogenesis [15]. Moreover, recent study
showed that tetraspanin, TM4SF promotes CSCs pheno-
type in breast cancer cells. Mechanistically, collagen I
but not IV, fibronectin and laminin 1 induces TM4SF-
mediated coupling of DDR1 to PKCα and augment
JAK2-STAT3 signaling which is essential for reactivation
of the dormant solitary tumor cells for establishment of
multi-organ site metastatic out growth [108].
The comparative analysis of monolayer vs 3D spheroid
showed that neural progenitor genes that includes ID4
(Inhibitor of DNA Binding 4) switched from 3D-
spheroid to highly differentiated morphology indicating
that ID4 plays a crucial role in the maintenance of CSCs
phenotype in melanoma cells [109]. In contrast, IGFBP5
acts as tumor suppressor in melanoma through attenu-
ation of stem-like cell activity (Fig. 2). IGFBP5 disrupt
the binding of IGF to IGFR1 leading to inactivation of
ERK1/2 and p38 MAPK pathway that preferentially at-
tenuates HIF1α regulated VEGF and MMPs gene expres-
sion [77]. Interestingly, TGFβ markedly induces EMT
phenotype in several cancers including breast and mel-
anoma. Schlegel et al. have demonstrated that PI3K and
PDGF signaling are important for TGFβ-induced EMT
in human melanoma cells. TGFβ activates SMAD signal-
ing which in turn regulates PDGF and its receptor ex-
pression leading to activation of PI3K-Akt pathway
which contributes EMT in melanoma [81]. TGFβ also
induces the amoeboid migration of melanoma cells
which is alternative of EMT. Downstream of TGFβ,
SMAD2 and its adaptor CITED1 regulate the amoeboi-
dal characteristic of melanoma cells. Moreover, TGFβ-
SMAD2-CITED1 signaling axis induces melanoma cell
attachment to endothelial cells, lung colonization and
metastatic out growth [82]. Rh123low (Low Rhodamine
123) cells exhibit stem-like phenotype correlate with en-
hanced levels of HIF1α, Oct4 and ABCB5 and reduced
level of Cyclin D1 and CDK4 which define the quiescent
and chemoresistance properties of CSCs in melanoma. It
has been also reported that PI3K/Akt pathway is in-
volved in the maintenance of Rh123low in melanoma
stem cell compartment [110]. Attenuation of PI3K/Akt
downregulates TNF-mediated enrichment of GFPhigh
label-retaining in CSCs in melanoma [111]. Vasculogenic
mimicry (VM) plays a crucial role in melanoma angio-
genesis. VEGF-A is a well known regulator of tumor
vascularisation. Inhibition of VEGFR2 kinase activity
with PTKi-II (protein tyrosine kinase inhibitor II) does
not affect VM in melanoma cells however, attenuation
of VEGFR1 significantly disrupts this process. In
addition, inhibition of PKCα abrogates vasculogenic
mimicry. Taken together, these data suggest that
VEGFR1 and PKCα signaling regulates VM in melanoma
[42]. In addition, deficiency of p63, a p53 homolog sup-
presses tumor growth. Interestingly, the isoform of p63,
ΔNp63α bypasses the senescence to promote stem-like
cell proliferation and tumorigenesis in skin cancer under
in vivo condition [112]. Moreover, ΔNp63α enhances the
expression and activation of Akt1 and p-Akt1 which
preferentially induces the proliferation and survival of
cancer cell [113]. Overall, all these data suggest that mo-
lecular signaling plays an important role in CSCs-
mediated melanoma progression (Fig. 2).
CSCs and microenvironment in melanoma
Like normal stem cells, CSCs are regulated by cell to cell
communications with their non-tumorigenic cancer
population or stromal cells to sustain their own inter-
discipline [114]. Tumor progression also depends on
several secreted factors or other niche component, site
of injection and species-species host milieu. Rao et al.
have demonstrated that tumor associated macrophage
(TAM) interacts with CSCs and secrete osteopontin
(OPN) which enhances the tumorigenicity and clono-
genicity in colorectal cancer [115]. These CSCs might
also reciprocally regulate surrounding niche through the
secretion of specific growth factor that regulates OPN
expression in TAM. Moreover, Kale et al. have shown
that macrophage in association with melanoma enhances
the OPN expression that further regulates Cox2 produc-
tion and controls melanoma growth and angiogenesis
[116]. Kumar et al. have also demonstrated that stromal
OPN enriches SP-phenotype which ultimately control
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melanoma progression [10]. Hypoxic microenvironment
plays an important role in tumor progression and con-
trols tumor stem cell population by stabilizing hypoxia
inducible factor (HIF) [117]. HIF1 and HIF2 are the sub-
family of hypoxia inducible transcription factors which
are activated in tumor hypoxic regions and are respon-
sible to initiate a complex set of cellular response in
tumor cells. It has been reported that HIF1α and HIF2α
are involved in invasion and invadopodia formation and
associated with melanoma metastases in patients. HIF1α
increases VEGF expression and decreases E-cadherin
levels that are crucial for angiogenesis and metastasis
[118, 119]. Furthermore, hypoxic microenvironment en-
riches the higher expression of CD133 and VEGFR2 as
compared with normoxic conditions that lead to en-
hanced melanoma growth [120]. Additionally, MFG-E8
induces VEGF and ET-1 expression in MSCs and en-
hances M2 macrophage polarization that leads to higher
angiogenesis and melanoma growth under hypoxic con-
ditions [121]. Taken together, these studies established
the role of tumor microenvironment in CSCs-mediated
melanoma progression.
Function of miRNA in melanoma specific CSCs
Several reports have suggested that miRNAs may act as
early diagnostic and prognostic biomarker in many can-
cers including melanoma [122]. Initially, miRNAs that
suppress or promote metastasis have been identified in
Fig. 2 Signaling involved in CSCs that mediates melanoma progression. Hedgehog signaling transcriptionally regulates E2F1 expression and promotes
iASPP expression leading to melanoma progression. BRAF (V600E) and NRAS (Q61K) signaling induce miR-146a through MYC. This miRNA enhances
the Notch signaling through downregulation of NUMB expression. Notch1 Intracellular Cleaved Domain (NICD1) translocates into the nucleus and
transcriptionally regulates the expression of CD133 that preferentially activates the p-38 MAPK pathway-mediated AP-1-DNA binding. Additionally,
AP-1-DNA binding also induced by Wnt signaling leading to higher melanoma metastasis and angiogenesis. IGF binds to their receptor (IGF1R) and
activates the phosphorylation of ERK and p38 that leads to HIF1α-DNA binding and maintain melanoma stem-like phenotype. Selected EMT modulator
such as TGFβ activates PI3K-Akt signaling pathway and induces amoeboidal cell migration and EMT phenotype in melanoma. iASPP: inhibitor of
apoptosis-stimulating protein of p53; NICD1: notch1 intracellular cleaved domain; MAPK: mitogen-activated protein kinases; IGF1R: insulin growth factor
receptor 1; IGFBP5: insulin growth factor binding protein 5; HIF: hypoxia-inducible factor; TGFβ: transforming growth factor beta; EMT: epithelial to
mesenchymal transition
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breast cancer [123, 124]. Subsequent studies have re-
vealed that many miRNAs regulate tumor growth, angio-
genesis and metastasis in various other cancers.
Additionally, the expression of miRNA strongly corre-
lates with various steps of melanoma progression (Fig. 1
and 2). Therefore, deregulation in miRNA expression
and function appears to be a pervasive feature of human
cancers (Table 2).
Several studies have shown that cluster of miRNA
such as miR-1908, miR-199a-3p and miR-199a-5p drive
metastatic invasion, endothelial recruitment and angio-
genesis. Further, these miRNA cooperatively attenuates
ApoE and DNAJA4 which are required for suppression
of cell invasion and endothelial recruitment by engaging
LRP1 and LRP8 that ultimately associates with meta-
static progression [125]. miRNA profiling revealed that
miR-125a-5p suppresses melanoma growth through
down regulation of TGFβ signaling by direct targeting
Lin28B, a well known inhibitor of Let-7 miRNA biogen-
esis. Further, clinical data indicated that Lin28B was ab-
errantly expressed in large number of melanoma
patients [126]. A direct plasma assay has been developed
to detect circulating miRNA-210 as indicator which can
be used for early metastatic recurrence in melanoma
under hypoxic environment [122]. In depth studies also
revealed that there are differential expression patterns of
miRs which correlate CSCs and EMT phenotypes. These
data suggest that metastasis and EMT associated miR-
10b, miR-21, miR-200c, miR-373 and miR-520c are
highly upregulated in melanosphere as compared with
monolayer [16]. Tumor derived exosomes also contain
miRNAs including miR-105 which help in destroying
the vascular endothelial barrier [17].
Noman et al. have shown that hypoxia-inducible miR-
210 regulates the susceptibility of tumor cells against cyto-
toxic T cells [127]. They have shown that hypoxia predom-
inantly induces miR-210 expression in melanoma cells
through HIF1α-dependent manner. Further, miR-210 con-
fers resistant in hypoxic tumor cells against cytotoxic T
cell-mediated lysis through targeting PTPN1, HOXA1 and
TP53I11 genes. The results speculate that this miRNA
must have role in immune suppression in hypoxic regions
of melanoma where CSCs and metastatic phenotypes are
known to evolve [127]. In contrast, other groups have
shown that hypoxia induces downregulation of miR-340-5p
expression which is responsible for upregulation of
melanoma-stem cell associated marker, ABCB5 [128]. Add-
itionally, overexpression of miR-200c in CD44+CD133+
CSCs resulted in downregulation of Zeb1 expression, re-
duction in cell proliferation, colony formation, cell migra-
tion and invasion as well as tumorigenic potential in
melanoma [129]. Moreover, miR-33b suppresses EMT and
migratory potential of melanoma cell by direct binding to
3’-UTR of HMGA2 and suppresses its expression [130].
miRNA also help in the communication between cancer
cell and their microenvironment. The co-culture of melan-
oma cells with astrocytes downregulates miR-768-3p
expression in melanoma cells which confer the chemoresis-
tance and CSCs properties [131]. Moreover, several other
miRNAs also act as mediator and communicators with
tumor-associated macrophage (TAM), cancer-associated
fibroblast (CAF), cancer-associated endothelial cell (CAEC)
and cancer-associated mesothelial cell (CAMC) [132]. Most
of the melanoma develops due to BRAF and NRAS muta-
tion. miR-146a is regulated by BRAF and NRAS genes as
shown by small RNA profiling. Further, BRAF-MEK-ERK
signaling enhances the expression of miR-146a through
transcriptional regulation and protein stability. Overexpres-
sion of miR-146a increases human melanoma cell prolifera-
tion and promotes tumor initiation by targeting NUMB
mRNA, a repressor of Notch signaling. A single nucleotide
C to G somatic mutation in miR-146a causes enhanced
Notch signaling and promotes oncogenesis [133]. Onco-
genic DNp73, a dominant-negative variant of tumor-
suppressor p73 confers enhanced stem-like properties in
melanoma through attenuation of miR-885-5p which regu-
lates IGF1R that is responsible for expression of stemness
marker [134]. Augmentation of miR-9 significantly de-
creases melanoma cell proliferation and migration. This
miRNA attenuates the expression of Snail1 with
Table 2 miRNAs associated with CSCs in melanoma
miRNA Functions References
miR-10b, miR-21, miR-200c, miR-373 and miR-520c Regulate EMT [16]
miR-340-5p Controls ABCB5 expression [128]
miR-200c Regulates Zeb1 expression, cell proliferation and invasion [129]
miR-33b Suppresses EMT and cell migration [130]
miR-885-5p Maintains stemness feature and controls proliferation and metastasis [134]
miR-9 Decreases proliferation and metastasis [135]
miR-155 Regulates NK cell activity [158]
miR-34a Target Notch1 signaling pathway [159]
miR-222 Controls Wnt and PI3K-Akt pathways and regulates CSCs phenotype [160]
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concomitant increase in E-cadherin expression. Mechanis-
tically, miR-9 binds to 3’-UTR of NF-κB and attenuates
their expression which preferentially inhibits Snail1 that ul-
timately leads to inhibition of melanoma cell proliferation
and metastasis [135].
Therapeutic implications of melanoma specific CSCs
Cancer stem cells rarely divide and have distinct cellular
physiology from the remaining bulk of tumor population.
Traditional chemotherapy and radiation therapy are not
sufficient to eradicate these CSCs from patients with can-
cer. Since CSCs have high level of transporter that pump
out chemotherapeutic agents which make CSCs more
chemoresistant. CSCs are also radio-resistant because of
preferential activation of DNA damage checkpoint and
DNA repair capacity [136]. In order to control melanoma
growth, it is necessary to target melanoma stem cells be-
cause it governs the recurrence of tumors and metastasis
after many years and may act as reservoir of therapeutic-
ally resistant cells.
Melanoma specific CSCs carry specific marker (CD133,
CD20, ABCB5, CD271 and ALDH1) or antigens, so target-
ing these cells using monoclonal antibodies could help to
combat melanoma growth. Rappa et al. have demonstrated
that downregulation of CD133 in human metastatic
melanoma cells (FEMX-1) attenuates the melanosphere
formation and metastatic potential. Further, monoclonal
antibodies against different epitopes of CD133 showed
dose-dependent cytotoxic effect [49]. Since melanoma spe-
cific CSCs express CD20, therefore rituximab therapy is
used in clinical trials to treat metastatic melanoma patients
by targeting CD20+ cells. The CD20 antibody therapy de-
pletes CD20 positive melanoma cells and eliminates per-
ipheral B cells that elevates in malignant melanoma
patients [26]. Vincristine (VCR) is commonly used for mel-
anoma therapy however it is ineffective against melanoma
specific CSCs. Song et al. investigated that VCR-containing
immuno-liposome conjugated with CD20 antibody (VCR-
Lip-CD20) is 1.85 fold more effective than VCR alone in
melanoma. They have further demonstrated that VCR-Lip-
CD20 selectively eliminates CD20+ melanoma cells and at-
tenuates tumorigenic ability of WM266-4 melanosphere
under in vivo condition [137]. Etoposide alone is not able
to eliminate CD133+ melanoma specific CSCs that express
high level of VEGFR2. However, combination of Etoposide
with Bevacizumab significantly induces apoptosis and abol-
ishes sphere-forming ability of CD133+ CSCs in melanoma
[120]. Schatton et al. have also demonstrated that there
was selective elimination of ABCB5 population in melan-
oma using a monoclonal antibody against ABCB5 under in
vivo mice model [5]. Recently, ABCB5+ cells in melanoma
have shown to suppress T cell activation and thus have spe-
cific role for immune evasion [5]. Therefore, targeting the
immune system in melanoma patient with IL-2 and IFN-α
could be important therapeutic approach [138]. Similarly,
Biasco et al. and Flaherty et al. have shown that Temozolo-
mide and Dacarbazine (DTIC) could be important thera-
peutic agents for treatment of metastatic melanoma [139,
140]. Since CSCs are also maintained by specific signaling
cascade therefore targeting these cells using DAPT (Notch
inhibitor), Cyclopamine (Hh signaling inhibitor), XAV939
(Wnt signaling inhibitor), or DTIC could be appropriate
strategies for treatment of melanoma patient [141–143]. In
addition, Demcizumab (anti-Notch ligand, DLL4 antibody),
OMP-52M51 (anti-Notch1 antibody), OMP-18R5 (anti-
Wnt receptor, FZD monoclonal antibody) and BBI608 (in-
hibitor of Stat3 and β-catenin pathways) could be better
therapeutic agents to combat melanoma [144] (Fig. 3). Re-
cent studies have shown that Andrographolide (Andro),
derived from Andrographis paniculata, attenuates tumor
growth through abrogation of Notch1-mediated CD133-
dependent p38 MAPK activation pathway in CD133+ mel-
anoma cells. In addition, Andro also impairs the EMT,
angiogenesis and metastasis properties of these CD133+
cells. Similar to DTIC, Dabrafenib or Trametinib those
commonly used for treatment of melanoma, Andro also
targets CD133+ CSCs and suppressed melanoma growth
and lung metastasis [15]. These data indicated that Andro
may act as a potential anti-cancer agent for the eradication
of CSCs-dependent melanoma progression.
Recent advancements in targeting Bcl2 family mem-
bers are an alternative option to combat melanoma and
overcome relapse or resistance of melanoma. To prevent
this relapse, it is necessary to develop effective therapies
that eradicate all subpopulation of tumor cells including
resistant CSCs subpopulation in melanoma. Bcl2 family
members play a crucial role in cancer resistance mech-
anism and contributes to chemoresistant ability of CSCs
and their survival [145, 146]. Several Bcl2 proteins are
downstream of commonly activated RAS/BRAF/MAPK
and PI3K/Akt signaling pathways which play an import-
ant role in tumor initiation and maintenance of melan-
oma specific CSCs compartment [146]. Small molecule
inhibitor such as BH3 mimetic which mimics the pro-
apoptotic BH3 protein and induces apoptosis is cur-
rently a successful approach. Additionally, ABT-263 is a
mimetic of BAD that inhibits anti-apoptotic proteins
such as Bcl2, Bcl-xl and Bcl-w [145, 146]. Another, small
molecule ABT-737 that inhibits Bcl2, Bcl-xl or Bcl-w is a
promising agent for treatment of cancers. Moreover,
synthetic retinoid fenretinide N-(4-hydroxyphenyl) reti-
namide (4-HPR) is another promising agent for the
management of breast cancer. Interestingly, the data
shown that combination of ABT-737 and 4-HPR signifi-
cantly eliminate ALDH+ CSCs in multiple melanoma
cell lines including BRAF and NRAS mutant cells [145].
Further, combination of anti-apoptotic MCL-1 protein
inhibitor, SC-2001 and ABT-737 significantly depletes
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ALDH+ cells in melanoma [147]. Most of the CSCs ex-
hibit chemoresistance through attribution of enhanced
drug efflux mediated by ATP-binding cassette sub family
B (ABCB). The results revealed that caffeic acid phe-
nethyl ester (CAPE), a bioactive molecule induces apop-
tosis in ABCB5 knocked down CD133+ chemoresistant
melanoma cells. CAPE activates E2F1 gene which trigger
apoptosis through mitochondrial dysfunction, ER stress
and induction of pro-apoptotic genes such as Bax, Noxa
and Puma. These observations suggest that combination
of ABCB5 siRNA and CAPE can de-bulk the tumor
mass and eliminate chemoresistance in melanoma spe-
cific CSCs [148]. Recent study also demonstrates that in-
hibition of deacytylase activity of Sirtuin 1 and 2 (SIRT1/
2) by Tenovin-6 induces apoptosis in uveal melanoma
by upregulating the expression of tumor suppressor
gene, p53 and elevation of ROS. Tenovin-6 eliminates
the ALDH+ CSCs compartments and inhibits the growth
and migration of uveal melanoma [149].
Despite recent advances in immunotherapy for cancer,
the efficacy of this strategy remains limited. Several stud-
ies have indicated that CSCs are weak in immunogen-
icity due to low expression of antigens which is one of
the prime obstacles for induction of anti-tumor immune
response. Overexpression of ESAT-6-gpi and IL-21 anti-
gens in CD133+CD44+ melanoma specific CSCs en-
hanced the levels of anti-ESAT-6 and interferon (IFN)-γ
as well as increased cytotoxic activities of NK cells, sple-
nocytes and complement dependent cytotoxicity leading
to attenuation of melanoma growth and metastases [53]
(Fig. 3). Moreover, ALDHhigh melanoma CSCs lyaste-
pulsed dendritic cells (DCs) act as a better vaccine which
Fig. 3 Molecular targeted therapy in melanoma CSCs. mAbs against FZD receptor, DLL4, Notch1, CD133, CD20 or ABCB5 attenuates the CSCs-dependent
melanoma progression. Abrogation of Notch1, Hedgehog and Wnt siganling using DAPT, Andro, Honokiol, Cyclopamine or XAV939 depletes CSCs in
melanoma. Anti-apoptotic small molecule inhibitors such as ABT-263 and a SIRT1 inhibitor, Tenovin-6 induce apoptosis and suppress CSC-mediated
melanoma growth. Overexpression of ESAT-6gpi/IL-21 antigen sensitizes CSCs against NK cell-mediated apoptosis. MRP1-CD28 bivalent aptamers attenuate
drug-resistance of CSCs in melanoma. CSCs: cancer stem cells; Hh: hedgehog; Fz: frizzled; DAPT: N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine
t-butyl ester, a γ-secretase inhibitor; SIRT1: sirtuin 1; ESAT-6gpi: 6 kDa early secreted antigenic target (ESAT-6) in the glycosylphosphatidylinositol
(GPI)-anchored form; IL-21: interleukin-21; NK cells: natural killer cells; MRP1: multidrug resistant proteins 1; CTX: cyclophosphomide
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leads to significant reduction in tumor growth and lung
metastases. Further, administration of ALDHhigh CSCs-
DC vaccine significantly attenuates ALDHhigh CSCs per-
centage in primary tumors through specific binding of
IgG produced by primed B cell resulting in lysis of target
cells in the presence of complement [150]. Recent study
revealed a novel bi-specific aptamer which have two CD28
motifs and able to costimulate T lymphocytes and pro-
motes tumor immunity. Other MRP1 motif that is capable
to bind MRP1 aptatope of chemoresistant CSCs. The in
vivo results revealed that systemic administration of
MRP1-CD28 bi-valent aptamer exhibits higher concentra-
tion in B16-MRPhigh tumor as compared with B16 paren-
tal tumors which leads to downregulation of B16-MRPhigh
tumor growth efficiently [151].
Several studies have indicated that CD44 is a CSC
marker in various cancers including melanoma. It binds
specially to hyaluronic acid. Shen et al. have demon-
strated that coating solid lipid nanoparticles with hyalur-
onan (HA-SLNs) allowed targeted delivery of Paclitaxel
(PTX) to CD44+ B16F10 melanoma cells. PTX loaded
HA-SLNs significantly abrogate tumor growth and lung
metastasis [152]. Additionally, combined treatment with
engineered VNP20009, carrying shABCB5 and Cyclo-
phosphomide (CTX) drastically reduced ABCB5+ CSCs
that leads to attenuation of melanoma tumor growth
and enhanced survival time [153]. Blocking Hedgehog-
GLI signaling with smoothened (SMO) and GLI antag-
onist by Cyclopamine and Gant61 remarkably attenuates
tumor initiating properties of ALDHhigh melanoma stem
cells [100]. Moreover, Honokiol (HNK), a biphenolic
natural compound reduces the expression of various
stem cell markers such as CD271, CD166, JARID1B
and ABCB5 in melanoma. Furthermore, HNK also
significantly attenuates CSC properties through inhib-
ition of Notch signaling [104]. Therefore, understand-
ing the signaling cross-talk, tumor microenvironment
and identification of novel targets in CSCs may allow
us for more effective combinatorial antitumor therap-
ies (Fig. 3).
Limitation, barriers and controversy in melanoma specific
CSCs
It has long been recognized that tumors are heteroge-
neous in nature that is being confirmed with several
functional and phenotypic properties to validate the ex-
istence of CSCs in many cancer including melanoma.
After several decades, debates still continues whether
melanoma contain CSCs and the origin of melanoma
CSCs. The identification and characterization of CSCs
may help in the elimination of CSCs in melanoma. How-
ever, CSCs have several limitations such as they exihibit
normal stem cell like self-renewal property, DNA repair
mechanism, oxidative state and resistance to xenobiotic
toxins. Therefore, targeting CSCs in tumor might also
affect normal stem cells and hence distinct molecular
features of CSCs need to be established for the manage-
ment of CSC-mediated therapy in melanoma [154].
Several lines of evidences indicate that CSCs present in
the melanoma which in turn responsible for diseases pro-
gression [3–6]. In contrast, Quintana et al. have exten-
sively demonstrated that phenotypic heterogeneity among
tumorigenic melanoma cells is reversible and not hier-
archically organized [155]. Additionally, other study
showed that only rare human melanoma cells (0.1-
0.0001%) are able to induce tumor upon transplantation
into NOD/SCID mice model. However, using a highly im-
munocompromised NOD/SCID interleukin-2 receptor
gamma chain null (Il2rg−/−) mice model demonstrate that
approximately 25% of unselected melanoma cells formed
tumor [156]. These results indicate that melanoma does
not follow CSCs model and the percentage of tumorigenic
cells is common that depends on tumor microenviron-
ment. Moreover, Boiko et al. have showed that CD271+
melanoma cells exhibit CSCs properties that depend on
immunocompromised mouse strain, site of injection and
cell suspension preparation [90]. These observation sug-
gested that the tumorigenic potential of CSCs also de-
pends on the arrival of the fresh tissue from surgical
theatre, process of obtaining a single cells suspension to
derive highest number of viable cells, exclusion of dead
cells and debris, flow cytometry sorting of CSCs with high
yield and purity and transplantation time into recipient
model after sorting. The intrinsic tumorigenic potential of
human melanoma CSCs also defined by microenviron-
ment in immunocompromised mice model. Therefore, it
is critical to assess the relevance of CSCs hypothesis in
melanoma using appropriate model system [157]. In
addition, we have recently demonstrated that melanoma
are heterogeneous in nature. CD133+ CSCs derived from
melanoma cells exhibit long term tumorigenic potential in
isograft mice model which partly exclude the possibility of
the artificial milieu [15]. These data demonstrate that
functional studies are required to identify and characterize
CSCs population. Additional studies are needed in order
to understand the pathophysiological function of CSCs in
tumor progression.
Conclusions and future directions
Malignant melanoma is a deadly disease with historically
poor prognosis. Due to presence of heterogeneous sub-
population and existence of CSCs, it is difficult to com-
pletely cure such a devastating disease. The continued
attempt for the identification of CSCs in melanoma and
other cancers led to promise the field of CSCs research in
order to understand the management of cancers. CSCs ex-
hibit extensive contribution in tumor growth, angiogenesis
and reactivation in metastatic out growth through several
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genetic and epigenetic changes, EMT or stromal microen-
vironmental factors. CSCs are also responsible for thera-
peutic resistant that led to tumor relapse. Specific
signaling mechanisms are required for the maintenance of
CSCs in tumor that can maintain their microenvironment.
Therefore, CSCs are becoming priority targets for the de-
velopment of novel antitumor therapy.
The tumor milieu is a critical regulator of melanoma
specific CSCs-driven angiogenesis and metastasis. Signal-
ing effectors from ECM or stromal cells can act as EMT
or MET inducer or may regulate dormancy at metastatic
sites in CSCs. Furthermore, defined cellular programmes
allow CSCs to modify their milieu through the autocrine/
paracrine signals that increases invasiveness, metastasis
and angiogenesis. These programmes also promote CSCs
features and associate with the determination of the CSCs
fate. Several reports suggest that CSCs are more chemore-
sistant which show higher expression of drug efflux pump
and inhibitor of pro-apoptotic molecules. CSCs are weak
in immunogenic nature due to lack of expression of suffi-
cient antigens. Overexpression of specific antigens lead to
eradicate melanoma specific CSCs and attenuates tumor
progression. Several microRNAs such as miR-200c and
miR-33b act as suppressor through targeting specific sig-
naling cascade. It is known that miRNAs can interact with
many important regulatory pathways during CSC-
dependent melanoma progression such as MAPK/ERK
and PI3K/Akt. Therefore, identification of potential thera-
peutic agents that may regulate these specific miRNAs
which will allow to eradicate the root cause of melanoma
development, angiogenesis and metastasis. Considering
the unique biology of CSCs, there is great need to develop
novel and promising approaches for CSCs targeted cancer
therapy. Several studies indicate that controversy of mel-
anoma CSCs arises due to inappropriate mice model and
lack of proper functional assays. Considering the con-
troversy, limitation and barriers targeting CSCs, future
direction of research are needed to establish or iden-
tify the distinct features of CSCs with compared to
normal stem cells. In this review, we have discussed
that there are several small molecule inhibitors (HNK,
ABT-737, ABT-263), nanoparticles conjugated drugs
(HA-SLNs-PTX), signaling antagonist (Cyclopamine,
Gant61), monoclonal receptor antibodies (anti-CD20,
anti-CD133, anti-ABCB5) and microRNAs (miR-200c,
miR-33b) those could be used as novel therapeutic
strategies for management of melanoma. In addition,
recent data showed that Andrographolide may act as
a potent anti-cancer agent by targeting Notch1 path-
way in CSCs that ultimately suppresses malignant
melanoma growth (Fig. 3). Moreover, additional stud-
ies are required to target root cause of melanoma
growth and metastasis using personalized and com-
bination therapy.
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